167 related articles for article (PubMed ID: 36823199)
1. The predictive model for risk of chemotherapy-induced thrombocytopenia based on antineoplastic drugs for solid tumors in eastern China.
Zhou S; Song B; Li C; Tang W; Zhang X; Jin X; Xu X; Wang Q; Zheng H; Fu J
Sci Rep; 2023 Feb; 13(1):3185. PubMed ID: 36823199
[TBL] [Abstract][Full Text] [Related]
2. A Prediction Model for Chemotherapy-Induced Thrombocytopenia Based on Real-World Data and a Close Relationship Between AST/ALT Ratio and Platelet Count in Patients with Solid Tumors.
Song B; Zhou S; Li C; Zheng H; Zhang X; Jin X; Fu J; Hu H
Int J Gen Med; 2022; 15():8003-8015. PubMed ID: 36345528
[TBL] [Abstract][Full Text] [Related]
3. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice.
Weycker D; Hatfield M; Grossman A; Hanau A; Lonshteyn A; Sharma A; Chandler D
BMC Cancer; 2019 Feb; 19(1):151. PubMed ID: 30764783
[TBL] [Abstract][Full Text] [Related]
4. Predicting chemotherapy-induced thrombocytopenia in cancer patients with solid tumors or lymphoma.
Razzaghdoust A; Mofid B; Zangeneh M
J Oncol Pharm Pract; 2020 Apr; 26(3):587-594. PubMed ID: 31315547
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced thrombocytopenia in pediatric oncology: Scope of the problem and opportunities for intervention.
Degliuomini MD; Armstrong K; Mauguen A; Slotkin EK; Roberts SS; Dunkel IJ; Clouser M; Ortiz MV; Soff GA
Pediatr Blood Cancer; 2022 Oct; 69(10):e29776. PubMed ID: 35593014
[TBL] [Abstract][Full Text] [Related]
6. Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.
Al-Samkari H
Blood Rev; 2024 Jan; 63():101139. PubMed ID: 37914568
[TBL] [Abstract][Full Text] [Related]
7. Occurrence and Management of Thrombocytopenia in Metastatic Colorectal Cancer Patients Receiving Chemotherapy: Secondary Analysis of Data From Prospective Clinical Trials.
Kilpatrick K; Shaw JL; Jaramillo R; Toler A; Eisen M; Sangaré L; Soff GA
Clin Colorectal Cancer; 2021 Jun; 20(2):170-176. PubMed ID: 33281065
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors.
Hitron A; Steinke D; Sutphin S; Lawson A; Talbert J; Adams V
J Oncol Pharm Pract; 2011 Dec; 17(4):312-9. PubMed ID: 20823048
[TBL] [Abstract][Full Text] [Related]
9. A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies.
Al-Samkari H; Parnes AD; Goodarzi K; Weitzman JI; Connors JM; Kuter DJ
Haematologica; 2021 Apr; 106(4):1148-1157. PubMed ID: 32499239
[TBL] [Abstract][Full Text] [Related]
10. [Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)].
Consensus Committee of Chemotherapy Induced Thrombocytopenia, Chinese Society of Clinical Oncology
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):714-720. PubMed ID: 30293399
[TBL] [Abstract][Full Text] [Related]
11. Management of Thrombocytopenia in Cancer Patients.
Mones JV; Soff G
Cancer Treat Res; 2019; 179():139-150. PubMed ID: 31317485
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors of Chemotherapy-Induced Thrombocytopenia After Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancies.
Li J; Wang W; Jiang K; Cui J; Wang C; Liang T; Wang Y; Liu S; Zhou W
J Gastrointest Cancer; 2024 May; ():. PubMed ID: 38713434
[TBL] [Abstract][Full Text] [Related]
13. Incidence, consequences, and predictors of serious chemotherapy-induced thrombocytopenia in nasopharyngeal carcinoma.
Zhang LL; Chen X; Huang YY; Liang CX; Qiang MY; Cai ZC; Zhan ZJ; Deng Y; Zhou JY; Huang HY; Guo X; Lv X
Cancer Med; 2023 Jul; 12(13):14084-14093. PubMed ID: 37212462
[TBL] [Abstract][Full Text] [Related]
14. Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.
Levin RD; Daehler M; Grutsch JF; Hall JL; Gupta D; Lis CG
BMC Cancer; 2010 Oct; 10():565. PubMed ID: 20955619
[TBL] [Abstract][Full Text] [Related]
15. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia.
Al-Samkari H; Soff GA
Expert Rev Hematol; 2021 May; 14(5):437-448. PubMed ID: 33926362
[No Abstract] [Full Text] [Related]
16. The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies.
Shaw JL; Nielson CM; Park JK; Marongiu A; Soff GA
Eur J Haematol; 2021 May; 106(5):662-672. PubMed ID: 33544940
[TBL] [Abstract][Full Text] [Related]
17. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia.
Elting LS; Rubenstein EB; Martin CG; Kurtin D; Rodriguez S; Laiho E; Kanesan K; Cantor SB; Benjamin RS
J Clin Oncol; 2001 Feb; 19(4):1137-46. PubMed ID: 11181679
[TBL] [Abstract][Full Text] [Related]
18. Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors.
Gao Y; Liu Q; Shen Y; Li Y; Shao K; Ye B; Shen Y; Zhou Y; Wu D
Platelets; 2022 Oct; 33(7):1024-1030. PubMed ID: 35040375
[TBL] [Abstract][Full Text] [Related]
19. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Soff GA; Miao Y; Bendheim G; Batista J; Mones JV; Parameswaran R; Wilkins CR; Devlin SM; Abou-Alfa GK; Cercek A; Kemeny NE; Sarasohn DM; Mantha S
J Clin Oncol; 2019 Nov; 37(31):2892-2898. PubMed ID: 31545663
[TBL] [Abstract][Full Text] [Related]
20. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007.
Wu Y; Aravind S; Ranganathan G; Martin A; Nalysnyk L
Clin Ther; 2009; 31 Pt 2():2416-32. PubMed ID: 20110050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
